4 terminated, 2 completed, 1 withdrawn. 7 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 4, Completed 2, Withdrawn 1 |
| Phase 1 | 5 | Completed 2, Terminated 2, Withdrawn 1 |
Follow birinapant: new trials by email Literature Review of birinapant trials Research Report on birinapant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC) Birinapant, Carboplatin, Laboratory Biomarker Analysis - High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma | Phase 1 / Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2018-08-01 | 2025-05-13 | |
| Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors Birinapant, Pembrolizumab - Solid Tumors | Phase 1 / Phase 2 | Terminated | Medivir | 34 | 2017-08-04 | 2021-01-14 |
| Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL birinapant, Azacitidine, Placebo - Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML) | Phase 2 | Terminated | TetraLogic Pharmaceuticals | 118 | 2014-06-01 | 2016-10-20 |
| Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy Birinapant, 5-Azacitidine - Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | TetraLogic Pharmaceuticals | 21 | 2013-06-01 | 2016-04-21 |
| Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer Birinapant (TL32711) - Epithelial Ovarian Cancer, Peritoneal Neoplasms | Phase 2 | Terminated | National Cancer Institute (NCI) | 11 | 2012-08-15 | 2017-05-30 |
| A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia Birinapant - Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Terminated | Abramson Cancer Center at Penn Medicine | 27 | 2011-11-01 | 2021-06-24 |
| Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors Birinapant - Cancer | Phase 1 / Phase 2 | Completed | TetraLogic Pharmaceuticals | 176 | 2010-10-01 | 2016-05-30 |
Fallopian Tube Neoplasms (2) · Myelodysplastic Syndromes (2) · Recurrence (2) · Carcinoma, Ovarian Epithelial (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Peritoneal Neoplasms (1)
TetraLogic Pharmaceuticals (3) · Abramson Cancer Center at Penn Medicine (1) · Jonsson Comprehensive Cancer Center (1) · Medivir (1) · National Cancer Institute (NCI) (1)
United States (7) · Australia (1) · Germany (1) · Spain (1)
Alex Adjei, MD, PhD (1) · Christina M Annunziata, M.D. (1) · Gautam Borthakur, MD (1) · John N Nemunaitis, MD (1) · Kyriakos P Papadopoulos, MD (1) · Lainie P Martin, MD (1) · Noelle Frey, MD (1) · Patricia LoRusso, DO (1) · Ravi Amaravadi, MD (1) · Sanaz Memarzadeh (1) · Zdenka Segota, MD (1)
2014 (1)